Skip to main content

Advertisement

SpringerLink
Log in

The Association between Calcitonin Gene-Related Peptide (CGRP), Substance P and Headache in Pituitary Tumours

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Objectives: To determine if the differential expression of calcitonin gene-related peptide (CGRP) or substance P (SP) in a range of pituitary tumours was related to the presence or absence of headache. Methods: Using recognised immunohistochemical techniques we examined twenty-six consecutive pituitary adenoma specimens for the presence of CGRP and SP. We included one normal post mortem pituitary specimen for comparison. A separate observer divided the patients into two groups: headache and non-headache. The association between the presence of CGRP, SP and headache was observed. Results: We observed CGRP in seven specimens (27%) and SP in six tumour specimens (23%), with cytoplasmic staining being the predominant morphological picture. CGRP and SP were co-expressed in the same tumour specimen in five cases. There was no significant association between the presence of CGRP and headache (χ2 0.86; P = 0.35). We did not observe CGRP or SP in the control specimen. There was no correlation between tumour subtype and the presence of CGRP or SP. Conclusions: The mechanism of pituitary tumour-associated headache remains undetermined. The significance of the presence of CGRP and SP in pituitary tumours is unknown but does not appear to be related to headache or endocrine activity of the tumour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abe T, Matsumoto K, Kuwazawa J, Toyoda I, Sasaki K. Headache associated with pituitary adenomas. Headache 1998;38:782–786.

    Article  CAS  PubMed  Google Scholar 

  2. Hennessy JV, Jackson IM. Clinical features and differential diagnosis of pitutiary tumours with emphasis on acromegaly. Baillieres Clinical Endocrinology and Metabolism 1995;9:271–234.

    Google Scholar 

  3. Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:23–240.

    Google Scholar 

  4. Nabarro JD. Acromegaly. Clinical Endocrinology 1987;26: 481–512.

    CAS  PubMed  Google Scholar 

  5. Couch J. Toxic and metabolic headache. Handbook of Clinical Neurology. Amsterdam: Elsevier, 1986:417–430.

    Google Scholar 

  6. Edvinsson L, Goadsby PJ. Neuropeptides in the cerebral circulation: Relevance to headache. Cephalalgia 1995;15:272–278.

    CAS  PubMed  Google Scholar 

  7. Levy MJ, Jager HR, Matharu MS, Goadsby PJ. Pituitary tumours and headache: Does size matter? Cephalalgia 2002;22:592.

    Google Scholar 

  8. Pascual J. Headache relief after sumatriptan in a patient with pituitary macroadenoma. Headache 2000;40:399–400.

    CAS  PubMed  Google Scholar 

  9. Williams G, Ball J, Bloom S, Joplin GF. Improvement in headache associated with prolactinoma during treatment with somatostatin analogue: An “N of 1” study. New England Journal of Medicine 1986;315:1166–1167.

    CAS  PubMed  Google Scholar 

  10. Millan Guerrero RO, Isais Cardenas MA. Headache associated with pituitary adenomas. Headache 1999;39:522–523.

    Article  CAS  PubMed  Google Scholar 

  11. Massiou H, Launay JM, Levy C, El Amran M, Emperauger B, Bousser M-G. SUNCT syndrome in two patients with prolactinomas and bromocriptine-induced attacks. Neurology 2002;58:1698–1699.

    CAS  PubMed  Google Scholar 

  12. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998;83: 3034–3040.

    Article  CAS  PubMed  Google Scholar 

  13. Pascual J, Freijares J, Berciano J, Pesquera C. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Pain 1991;47:341–344.

    Article  CAS  PubMed  Google Scholar 

  14. Williams G, Ball JA, Lawson RA, Joplin GF, Bloom SR, Maskill MR. Analgesic effect of somatostatin analogue (octreotide) in headache associated with pituitary tumours. British Medical Journal 1987;295:247–248.

    CAS  PubMed  Google Scholar 

  15. Levy MJ, Barakat M, Bejon P, Goadsby PJ, Meeran K. Acromegaly: A unique human headache model? Headache 2003;43:794–797.

    Article  PubMed  Google Scholar 

  16. Van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neuroscience and Biobehavioural Reviews 1997;21:649–678.

    CAS  Google Scholar 

  17. Gallai V, Sarchielli P, Floridi A, Franceschini M, Codini M, Trequattrini A, et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384–390.

    Article  CAS  PubMed  Google Scholar 

  18. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Annals of Neurology 1990;28:183–187.

    Article  CAS  PubMed  Google Scholar 

  19. Fanciullacci M, Alessandri M, Figini M, Geppetti P, Michelacci S. Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 1995;60:119–123.

    Article  CAS  PubMed  Google Scholar 

  20. Goadsby PJ, Edvinsson L. Human in vivoevidence for trigeminovascular activation in cluster headache. Brain 1994;117:427–434.

    PubMed  Google Scholar 

  21. Keller JT, Marfurt CF. Peptidergic and serotoninergic innervation of the rat dura mater. Journal of Comparative Neurology 1991;309:515–534.

    Article  CAS  PubMed  Google Scholar 

  22. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: Trigeminal origin and co-existence with substance P. Neuroscience Letters 1985;62:131–136.

    Article  CAS  PubMed  Google Scholar 

  23. Gibson SJ, Polak JM, Bloom SR, Sabate IM, Mulderry PM, Ghatei MA, et al. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. Journal of Neuroscience 1984;4:101–111.

    Google Scholar 

  24. Hokfelt T, Pernow B, Wahren J. Substance P: A pioneer amongst neuropeptides. Journal of Internal Medicine 2001;249:27–40.

    Article  CAS  PubMed  Google Scholar 

  25. Ribeiro-da-Silva A, Hokfelt T. Neuroanatomical localisation of substance P in the CNS and sensory neurons. Neuropeptides 2000;34:256–271.

    CAS  PubMed  Google Scholar 

  26. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Annals of Neurology 1988;23:193–196.

    Article  CAS  PubMed  Google Scholar 

  27. Steel JH, Gon G, Giaid A, O’Halloran DJ, Emson MA, Van Noorden S, et al. Localization of calcitonin gene-related peptide in the rat and human pituitary gland using immunocytochemistry and in situ hybridization. CGRP expression during ontogeny and after endocrine manipulations. Annals of the New York Academy of Sciences 1992;657:135–154.

    CAS  PubMed  Google Scholar 

  28. Jessop DS, Chowdrey HS, Larsen PJ, Lightman SL. Substance P: Multifunctional peptide in the hypothalamo-pituitary system? Journal of Endocrinology 1992;132:331–337.

    CAS  PubMed  Google Scholar 

  29. Wimalawansa S. Expression of CGRP in pituitary and pituitary adenoma. 76th Annual Meeting of the Endocrine Society. Anaheim, CA, 1994.

  30. Roth KA, Krause JE. Substance-P is present in a subset of thyrotrophs in the human pituitary. Journal of Clinical Endocrinology and Metabolism 1990;71:1089–1095.

    CAS  PubMed  Google Scholar 

  31. Levy MJ, Classey JD, Maneesri S, Powell M, Meeran K, Goadsby PJ. Differential expression of calcitonin gene-related peptide (CGRP) and substance P in pituitary adenomas: in search of a nociceptive peptide. Cephalalgia 2003;23:687.

    Google Scholar 

  32. Headache Classification Committee of The International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1–96.

    Google Scholar 

  33. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (2nd ed.). Cephalalgia 2004;24(Suppl 1): 1–160.

    Google Scholar 

  34. Burry RW. Specificity controls for immunocytochemical methods. Journal of Histochemistry and Cytochemistry 2000;48:163–165.

    CAS  PubMed  Google Scholar 

  35. Arita J, Kojima Y, Yamamoto I, Mazawa S, Kimura F. Somatotropes and thyrotropes in the rat anterior pituitary gland cosecrete substance P: Analysis by the sandwich cell immunoblot assay. Neuroendocrinology 1994;60:567–574.

    CAS  PubMed  Google Scholar 

  36. Edvinsson L, Goadsby PJ. Neuropeptides in headache. European Journal of Neurology 1998;5:329–341.

    Article  Google Scholar 

  37. Goadsby PJ, Lipton RB, Ferrari MD. Migraine- current understanding and treatment. New England Journal of Medicine 2002;346:257–270.

    Article  CAS  PubMed  Google Scholar 

  38. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003;23:519–527.

    CAS  PubMed  Google Scholar 

  39. Levy MJ, Matharu MS, Powell MP, Meeran K, Goadsby PJ. Phenoytpic characterisation of the headache associated with pituitary tumours. Cephalalgia 2003;23:621.

    Google Scholar 

  40. Afra J, Czirjak S. Headache characteristics in patients with pituitary tumours. Cephalagia 2003;23:671.

    Google Scholar 

  41. Greve E, Mai J. Cluster headache-like headaches: A symptomatic feature? A report of three patients with intracranial pathologic findings. Cephalalgia 1988;8:79–82.

    Article  CAS  PubMed  Google Scholar 

  42. Milos P, Havelius U, Hindfelt B. Clusterlike headache in a patient with a pituitary adenoma. With a review of the literature. Headache 1996;36:184–188.

    Article  CAS  PubMed  Google Scholar 

  43. Porta-Etessam J, Ramos-Carrasco A, Berbel-Garcia A, Martinez-Salio A, Benito-Leon J. Clusterlike headache as first manifestation of a prolactinoma. Headache 2001;41:723–725.

    Article  CAS  PubMed  Google Scholar 

  44. Levy MJ, Matharu MS, Goadsby PJ. Prolactinomas, dopamine agonist and headache: two case reports. European Journal of Neurology 2003;10:169–174.

    Article  CAS  PubMed  Google Scholar 

  45. Matharu MS, Levy MJ, Merry RT, Goadsby PJ. SUNCT syndrome secondary to prolactinoma. Journal of Neurology, Neurosurgery and Psychiatry 2003;74:1590–1592.

    Article  CAS  Google Scholar 

  46. Grouzmann E, Deruaz JP, Gomez F, Waeber C. Immunolocalization of neuropeptide Y in human pituitary tumours. Regulatory Peptides 1998;75:89–92.

    Article  PubMed  Google Scholar 

  47. Jansen I, Goadsby PJ, Uddman R, Edvinsson L. Vasoactive intestinal peptide (VIP) like peptides in the cerebral circulation. Journal of the Autonomic Nervous System 1994;49:S97-S103.

    Google Scholar 

  48. Hsu DW, Riskind PN, Hedley-Whyte ET. Vasoactive intestinal peptide in the human pituitary gland and adenomas. An immunocytochemical study. American Journal of Pathology 1989;135:329–338.

    Google Scholar 

  49. Suwanwela N, Phanthumchinda K, Kaoropthum S. Headache in brain tumor: A cross-sectional study. Headache 1994;34:435–438.

    Article  CAS  PubMed  Google Scholar 

  50. Ferrari MD, Haan J, van Seters AP. Bromocriptine-induced trigeminal neuralgia attacks in a patient with pituitary tumor. Neurology 1988;38:1482–1484.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Headache Group, Institute of Neurology, Queen Square, London

    M. J. Levy, J. D. Classey, S. Maneesri & P. J. Goadsby Professor

  2. Department of Endocrinology, Hammersmith/Charing Cross Hospitals Trust, London

    M. J. Levy, K. Meeran & P. J. Goadsby Professor

  3. Department of Neurosurgery, The National Hospital for Neurology and Neurosurgery, Queen Square, London

    M. Powell

  4. Headache Group, Institute of Neurology, Quen Square, London, WCOM 3BG, UK

    P. J. Goadsby Professor

Authors
  1. M. J. Levy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. D. Classey
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Maneesri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K. Meeran
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Powell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. J. Goadsby Professor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. J. Goadsby Professor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levy, M.J., Classey, J.D., Maneesri, S. et al. The Association between Calcitonin Gene-Related Peptide (CGRP), Substance P and Headache in Pituitary Tumours. Pituitary 7, 67–71 (2004). https://doi.org/10.1007/s11102-005-5347-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-005-5347-z

Key Words

Search

Navigation